- Home
- DLY vs ANAB Comparison
DLY vs ANAB Comparison
Compare DLY & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- ANAB
- Stock Information
- Founded
- DLY 2019
- ANAB 2005
- Country
- DLY United States
- ANAB United States
- Employees
- DLY N/A
- ANAB N/A
- Industry
- DLY Investment Managers
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- DLY Finance
- ANAB Health Care
- Exchange
- DLY Nasdaq
- ANAB Nasdaq
- Market Cap
- DLY 759.6M
- ANAB 621.1M
- IPO Year
- DLY N/A
- ANAB 2017
- Fundamental
- Price
- DLY $15.40
- ANAB $25.92
- Analyst Decision
- DLY
- ANAB Buy
- Analyst Count
- DLY 0
- ANAB 10
- Target Price
- DLY N/A
- ANAB $44.25
- AVG Volume (30 Days)
- DLY 215.9K
- ANAB 475.3K
- Earning Date
- DLY 01-01-0001
- ANAB 08-04-2025
- Dividend Yield
- DLY 8.93%
- ANAB N/A
- EPS Growth
- DLY N/A
- ANAB N/A
- EPS
- DLY N/A
- ANAB N/A
- Revenue
- DLY N/A
- ANAB $111,872,000.00
- Revenue This Year
- DLY N/A
- ANAB N/A
- Revenue Next Year
- DLY N/A
- ANAB $24.39
- P/E Ratio
- DLY N/A
- ANAB N/A
- Revenue Growth
- DLY N/A
- ANAB 387.20
- 52 Week Low
- DLY $13.26
- ANAB $12.21
- 52 Week High
- DLY $15.95
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- DLY 45.52
- ANAB 61.04
- Support Level
- DLY $15.33
- ANAB $23.10
- Resistance Level
- DLY $15.51
- ANAB $27.47
- Average True Range (ATR)
- DLY 0.09
- ANAB 1.22
- MACD
- DLY -0.01
- ANAB 0.15
- Stochastic Oscillator
- DLY 33.93
- ANAB 72.39
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).